The Cameron Institute

Canadians need to talk about their healthcare, about who pays for what, when. Lack of money is not the issue; how that money is spent is the issue—what public healthcare is covering and not covering. The same dollar amount can be spent quite differently and more effectively. The 1950s first-dollar, single-payor decision shifted the burden

Today, 25% of Canadians live in rural and remote parts of Canada. The evidence is that these Canadians do not enjoy the same health status as citizens living in more urban settings. This article explores four persistent healthcare challenges: population demographics, place, professionals, and public participation. By exploring solutions that some rural communities have used

The Patented Medicine Prices Review Board has seen a turbulent 30-year history, and it’s time for a review of legislation that employs ambiguous terms and standards. We need a new perspective of the health system that does not revolve around drug price and voids the concept that one can easily identify and “solve” excessive prices.

Urinary incontinence (UI) and fecal incontinence (FI) are embarrassing and debilitating conditions that are becoming collectively a major, growing health concern for men and women of all ages worldwide. In terms of academic study, interest and understanding, fecal incontinence (FI) is the poor cousin of the incontinence twins. Recent research from the Canadian Continence Foundation

There has been a lot of debate about national pharmacare coverage of catastrophic drug costs in government, the media, and among health policy experts, yet patients— who will be the ones most affected—have rarely had their say. To get a better understanding of what patients value in terms of a national drug coverage program The

In 1990, the government’s Ontario Provincial Inquiry into the Acquisition, Distribution, Dispensing, and Prescribing of Pharmaceutical Medicines in Ontario Inquiry, chaired by Frederick H. Lowy, submitted its report, entitled Prescriptions for Health. Dr. W. Spitzer of McGill University in Montreal, Quebec, chaired the Inter-University Working Group, which submitted a paper to the Lowy Commission of

While provinces are attached to reducing prices of drugs, the driver of cost is utilization. Many Canadians do not have drug insurance benefits and those that do find themselves covering many costs out-of-pocket. We’re seeing a number of patients suffer while misinformation about drug costs spreads, the pharmaceutical industry is vilified and government inaction on

Despite the availability of essential medicines in developing countries, one-third of the world’s population does not have access to essential medicines due to barriers including money, power, politics, and ideologies. Market failures and lack of political will to create stable, ethical and law-abiding government administrations that can support infrastructure and resources should carry a significant amount

Pharmaceutical models being touted for Canada do more harm than good for patients in need of innovative but expensive care. The following slides are from The Cameron Institute executive director Wayne Taylor’s presentation to the Best Medicine Coalition’s recent annual conference.

By D. Wayne Taylor East Bay Times guest commentary In June 2016, the United Nations is expected to issue recommendations for expanding access to medicines in developing countries. The panel’s proposals will almost certainly fall short. Secretary-General Ban Ki-moon convened his High-Level Panel on Access to Medicines in November 2015 to develop “solutions for remedying